{"id":916255,"date":"2025-12-04T08:15:17","date_gmt":"2025-12-04T13:15:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/"},"modified":"2025-12-04T08:15:17","modified_gmt":"2025-12-04T13:15:17","slug":"neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/","title":{"rendered":"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium"},"content":{"rendered":"
\n

\n Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest<\/em>\n <\/p>\n

\n Urges Stockholders to Vote \u201cFOR\u201d BOTH\u00a0of Neuphoria\u2019s Nominees on the\u00a0WHITE\u00a0Proxy Card<\/em>\n <\/p>\n

BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (\u201cNeuphoria\u201d or the \u201cCompany\u201d) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP\u2019s (\u201cLynx1\u201d), revised indication of interest to acquire the Company.<\/p>\n

\n Lynx1 Operating Outside Neuphoria\u2019s Robust and Ongoing Strategic Alternatives Review Process<\/strong>\n <\/p>\n

As previously announced, the Board \u2013 with assistance of its independent financial and legal advisors \u2013 is in the midst of a robust and comprehensive review of strategic alternatives to consider alternative assets, strategic pathways and\/or to advance the Company\u2019s promising pipeline program to maximize value for all stockholders. The Company has paused its research and development expenditures for BNC210 in PTSD and is evaluating all possibilities as part of the Company\u2019s strategic review. This process is well underway and the Company has received substantial reciprocal interest from potential counterparties across a range of sectors. In addition, several parties have already engaged with the Company under confidentiality arrangements, and discussions are ongoing through the Company\u2019s financial advisor, H.C. Wainwright & Co, and its independent legal advisors. The Board is continuing to evaluate all proposals, including the new unsolicited proposal submitted by Lynx1. The Board, in consultation with its advisors, will review Lynx1\u2019s new proposal in the same manner that it reviews any other proposals received as part of its strategic alternative review process and subject it to all the same processes and procedures that apply to any other proposal \u2013 despite Lynx1\u2019s seeming determination to operate outside that process, the only such party doing so at this time<\/strong>.<\/p>\n

The Company believes it is important for stockholders to understand that the Company\u2019s actions reflect a thoughtful and proactive strategy for the Company\u2019s future\u2014not a reactive one. A substantial amount of advanced planning for this strategic review was completed before the data readout of the AFFIRM-1 Phase 3 trial of BNC210 in SAD, which enabled the Company to launch the strategic review process expeditiously. The Company\u2019s strategy has been built through meticulous work, including meetings with external stakeholders, comprehensive internal diligence, and constructive discussions with the Food and Drug Administration. The Board remains fully committed to executing this strategic review process, with the goal of delivering substantial value for all stockholders.<\/p>\n

\n Lynx1\u2019s Revised Bid Does Not Appropriately Value the Company <\/strong>\n <\/p>\n

The Board has carefully evaluated Lynx1\u2019s new unsolicited proposal. The new bid is lower than its initial bid at $4.75 per share and reflects no meaningful premium to stockholders and is priced near estimated cash value. Neuphoria holds valuable licensing agreements with its strategic partners that have already generated tens of millions in revenue, with the potential for multiples of that in future milestone or other payments. Lynx1\u2019s proposal fails to reflect the value of these assets or the optionality they provide to the Company. Electing Lynx1\u2019s nominees would jeopardize the Board\u2019s ability to fully independently evaluate these agreements and any strategic alternatives, including potential offers. Lynx1\u2019s proposal risks transferring significant option value from all stockholders to an activist group without appropriate compensation.<\/p>\n

While the Board remains open to all paths that enhance stockholder value, the Company will NOT pursue any transaction that undervalues the Company from a commercial perspective, ignores participants that form an important part of the Company\u2019s stakeholders, and prematurely truncates and avoids the robust ongoing strategic review. Simply stated, Lynx1\u2019s non-binding proposal does not present an attractive value, and certainly not one that would compel the Board to consider abandoning its ongoing strategic review process \u2013 especially given that the Company has already received a substantial number of competing indications of interest, with nearly a dozen that have already advanced to NDAs and separate process letter proposals. The Company will evaluate the Lynx1 proposal as part of its consideration of all the offers it has received \u2013 but not to the exclusion of other viable offers.<\/p>\n

In addition, if Lynx1 succeeds in electing its nominees, their directors may favor Lynx1\u2019s proposal, rather than objectively evaluating all proposals received. This creates a significant risk that superior, more value-enhancing, or better-aligned strategic opportunities may be disregarded or never fully considered. For this reason, we strongly urge you to stand firm with the Company\u2019s Board by supporting the election of the Company\u2019s existing highly qualified and experienced Board nominees\u2014whose only interest is protecting and maximizing value for ALL our stockholders<\/strong>.\u00a0\u00a0<\/p>\n

\n Revised Lynx1 Bid Does Not Consider our Complex Agreements<\/strong>\n <\/p>\n

Lynx1 has not done sufficient diligence on the Company before submitting their new reduced price and reduced premium bid, as it significantly undervalues the Company\u2019s potential based on its relationships, and by not conducting proper due diligence, Lynx1 fails to take into consideration the complex nature of Neuphoria\u2019s existing contractual arrangements.<\/p>\n

\n Lynx1 Complains About Not Receiving Special Treatment, While Acting Outside the Strategic Review Process<\/strong>\n <\/p>\n

Neuphoria and its financial advisors have been diligently working to conduct a thorough and fair strategic review process, providing all interested parties with the same information and documentation. In fact, Lynx1 received the same non-disclosure agreement as all other interested parties and became quite upset that they were being asked to sign a typical non-disclosure agreement for a strategic review process seemingly because they feared it would prohibit them from continuing its self-interested proxy contest. Lynx1 returned comments to the Company on the non-disclosure agreement that were off market in that they entirely deleted the customary standstill provision, and in response the Company acting in good faith sent Lynx1 back a revised agreement that specifically exempted Lynx1\u2019s proxy contest from the standstill provisions. The Company intends to be fair and treat all bidders in a similar fashion, including Lynx1, even though Lynx1 seems to be expecting special treatment due to their ongoing proxy contest.<\/p>\n

In addition, by submitting a new and lower unsolicited bid, Lynx1 is trying to circumvent the Company\u2019s ongoing strategic review process and inexplicably hoping to get preference over the other interested parties. The Company plans to stay the course and continue with their thorough strategic review process in order to meet their goal of maximizing stockholder value.<\/p>\n

The Company therefore urges stockholders to vote \u201cFOR\u201d<\/strong>BOTH<\/strong> of Neuphoria\u2019s nominees \u2014 Davies and Wilson \u2014 and vote \u201cWITHHOLD\u201d <\/strong>on both of Lynx1\u2019s nominees on the WHITE<\/u><\/strong> proxy card TODAY<\/strong>. If you have any questions or need assistance voting please contact Sodali & Co at (203) 658-9400 or NEUP@investor.sodali.com.<\/p>\n

\n Advisors<\/strong>\n <\/p>\n

H.C. Wainwright & Co. is serving as financial advisor, and Rimon PC and Paul Hastings LLP are serving as legal counsel to Neuphoria. Sodali & Co is serving as proxy solicitor.<\/p>\n

\n About Neuphoria Therapeutics Inc.<\/strong>\n <\/p>\n

Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a public company incorporated in Delaware. The Company is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing the lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the \u03b17 nicotinic acetylcholine receptor for the treatment of post-traumatic stress disorder (\u201cPTSD\u201d). BNC210 is a first-of-its-kind, well tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Following the announcement from the AFFIRM-1 Phase 3 clinical trial on October 20, 2025, in which the Company announced that the trial missed its primary and secondary endpoints, the Company has halted development of BNC210 in social anxiety disorder and is conducting a strategic review. In addition, Neuphoria has a strategic partnership with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer\u2019s disease and other central nervous system conditions. Neuphoria\u2019s pipeline also includes the \u03b17 nicotinic acetylcholine receptor next generation and the Kv3.1\/3.2 preclinical programs, both in the lead optimization development stage.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201cpotential,\u201d \u201ccontinue\u201d or \u201cproject\u201d or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria\u2019s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and\/or completion, as well as any successful or other outcome of various clinical trials, and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat central nervous system diseases and pain conditions, and the Company\u2019s ability to realize the commercial potential of its products, as well as its regulatory strategy related to its clinical trials and, if successful, the regulatory pathway to any next stage in development or commercialization, (3) Neuphoria\u2019s financial resources, and capital allocation and corporate development strategy, (4) the Board\u2019s review of strategic alternatives and evaluation of offers from third parties, and (5) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. Certain forward-looking statements involve contracts, licenses and arrangements involving third parties and their respective clinical trial and research and development projects that are out of our control, including our agreements with our strategic partners. They may terminate or delay any or all such projects in their discretion pursuant to the terms of our agreements with them, which could result in the Company not realizing any further milestone payments or further progress on the respective product pathways. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company\u2019s business and other risks described in the Company\u2019s filings with the SEC, including the Company\u2019s Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Reports on Form 8-K, each filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria\u2019s filings with the SEC, copies of which are available from the SEC\u2019s website (www.sec.gov<\/a>) and on Neuphoria\u2019s website (www.neuphoriatx.com<\/a>) under the heading \u201cInvestor Center.\u201d All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.\u00a0<\/strong><\/p>\n

\n FOR FURTHER INFORMATION PLEASE CONTACT:<\/strong>\n <\/p>\n

\n General<\/u>\n <\/p>\n

Spyridon (Spyros) Papapetropoulos
spyros@neuphoriatx.com<\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n IR & PR<\/u>\n <\/p>\n

Argot Partners
neuphoria@argotpartners.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote \u201cFOR\u201d BOTH\u00a0of Neuphoria\u2019s Nominees on the\u00a0WHITE\u00a0Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (\u201cNeuphoria\u201d or the \u201cCompany\u201d) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP\u2019s (\u201cLynx1\u201d), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria\u2019s Robust and Ongoing Strategic Alternatives Review Process As previously announced, the Board \u2013 with assistance of its independent financial and legal advisors \u2013 is in the midst of a robust and comprehensive … <\/p>\n

Continue reading “Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-916255","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote \u201cFOR\u201d BOTH\u00a0of Neuphoria\u2019s Nominees on the\u00a0WHITE\u00a0Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (\u201cNeuphoria\u201d or the \u201cCompany\u201d) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP\u2019s (\u201cLynx1\u201d), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria\u2019s Robust and Ongoing Strategic Alternatives Review Process As previously announced, the Board \u2013 with assistance of its independent financial and legal advisors \u2013 is in the midst of a robust and comprehensive … Continue reading "Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T13:15:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium\",\"datePublished\":\"2025-12-04T13:15:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/\"},\"wordCount\":1940,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/\",\"name\":\"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=\",\"datePublished\":\"2025-12-04T13:15:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/","og_locale":"en_US","og_type":"article","og_title":"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium - Market Newsdesk","og_description":"Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote \u201cFOR\u201d BOTH\u00a0of Neuphoria\u2019s Nominees on the\u00a0WHITE\u00a0Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (\u201cNeuphoria\u201d or the \u201cCompany\u201d) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP\u2019s (\u201cLynx1\u201d), revised indication of interest to acquire the Company. Lynx1 Operating Outside Neuphoria\u2019s Robust and Ongoing Strategic Alternatives Review Process As previously announced, the Board \u2013 with assistance of its independent financial and legal advisors \u2013 is in the midst of a robust and comprehensive … Continue reading \"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-04T13:15:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium","datePublished":"2025-12-04T13:15:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/"},"wordCount":1940,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/","name":"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=","datePublished":"2025-12-04T13:15:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Njc2MCM3MzA1ODg5IzIyNDQxNzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-reduced-price-and-premium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuphoria Responds to Lynx1\u2019s Revised Indication of Interest at a Reduced Price and Premium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/916255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=916255"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/916255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=916255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=916255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=916255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}